Schwarz Pharma's Rotigotine CDS will Overtake GlaxoSmithKline's Requip as the Clinical Gold Standard for the Treatment of Restless Legs Syndrome by 2009

WALTHAM, Mass., April 17 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Schwarz Pharma's rotigotine CDS will overtake GlaxoSmithKline's Requip as the clinical gold standard for the treatment of restless legs syndrome by 2009. According to the new report entitled Large Opportunity for Novel and "Me Too" Drugs Entering the Market: A Restless Legs Syndrome Study, much of rotigotine CDS's success will be attributable to being delivered in a patch.

"Some patients believe patches offer a better side-effect profile, and experts note that patients using patches are often more compliant than patients taking a pill," said Julie Kerner, Ph.D., analyst at Decision Resources. "Transdermal patches approved to treat restless legs syndrome will likely be applied once daily regardless of disease severity; for this reason, they will offer improved dosing frequency to the most severely affected patients."

About Large Opportunity for Novel and "Me Too" Drugs Entering the Market: A Restless Legs Syndrome Study

Large Opportunity for Novel and "Me Too" Drugs Entering the Market: A Restless Legs Syndrome Study covers the current and future state of the restless legs syndrome drug market. The report includes:

  -- More than 3,000 physician responses that define drug attributes that
     drive prescription now and in the future.
    -- Clinical end point tradeoffs that are most influential to physicians.
    -- Areas of unmet need with highest potential.
    -- Benchmark trial results for specific drug opportunities.
    -- Patient share potential for emerging therapies and target product
       profiles.
  -- Decision Resources proprietary analysis of commercial factors that
     accelerate or constrain a drug's market potential.
    -- Promotion: DTC spend, detailing intensity.
    -- Reimbursement: formulary tier, prior approval restriction, quantity
       limits.
    -- Labeling: black box warnings, approved patient segments,
       contraindications.
    -- Competition: order of entry, pricing, generic entry, pipeline sales
       forecast.
    -- Medical practice: decision trees, treating physician type, line of
       therapy.
  -- Comparisons of the key clinical attributes of current and emerging
     therapies in the areas of efficacy, safety, and delivery.
  -- Analysis and supporting data that identifies the clinical "Gold
     Standard" now and over the next ten years.
  -- Key insights as to which clinical end points have the greatest
     influence on physician decision-making.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:
  Elizabeth Marshall
  Decision Resources, Inc.
  781-296-2563
  emarshall@dresources.com